Please assess the completion status of the following clinical trial:

Trial Title: Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* no history of spontaneous puberty~* clinical hypogonadism~* infantile testes (\< 3 ml)~* no reproductive hormone therapy except testosterone~* Complete absence of normal LH pulses during 12-hour baseline frequent blood sampling and serum testosterone \< 100 ng/dl~* Normal testing of the anterior pituitary gland~* Negative MRI of the hypothalamic-pituitary area~Exclusion Criteria~* Prior therapy with gonadotropins (FSH, hCG, or GnRH)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (FSH) (Type: EXPERIMENTAL): Patients in Group 1 will receive subcutaneous follicle stimulating hormone (FSH) injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.
- Group 2 (GnRH) (Type: ACTIVE_COMPARATOR): Patients in Group 2 will receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).